COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
NanoViricides, Inc. explains its drug strategy for combating viral infections and pandemics, focusing on development of antiviral nanomedicine drugs like NV-387 -
-
-
COMMUNIQUÉ DE PRESSE
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
NanoViricides, Inc. receives approval from CNES for Phase II clinical trial of NV-387 in DRC for MPox disease treatment. CEO highlights drug's broad-spectrum antiviral capabilities -
-
-
COMMUNIQUÉ DE PRESSE
Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
NanoViricides, Inc. provides details on its Measles drug development program targeting the endemic potential of the virus in the USA and the effectiveness of their broad-spectrum antiviral drug NV-387
